rs914048941
Positions:
Variant summary
Our verdict is Likely benign. Variant got -1 ACMG points: 1P and 2B. PP2BP4_Moderate
The NM_001161352.2(KCNMA1):c.16G>A(p.Gly6Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000129 in 1,523,288 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.000079 ( 0 hom., cov: 32)
Exomes 𝑓: 0.00013 ( 0 hom. )
Consequence
KCNMA1
NM_001161352.2 missense
NM_001161352.2 missense
Scores
3
4
12
Clinical Significance
Conservation
PhyloP100: 0.939
Genes affected
KCNMA1 (HGNC:6284): (potassium calcium-activated channel subfamily M alpha 1) This gene encodes the alpha subunit of calcium-activated BK channel. The encoded protein is involved in several physiological processes including smooth muscle contraction, neurotransmitter release and neuronal excitability. Mutations in this gene are associated with a spectrum of neurological disorders including Paroxysmal Nonkinesigenic Dyskinesia 3, Idiopathic Generalized Epilepsy 16 and Liang-Wang syndrome. [provided by RefSeq, Aug 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -1 ACMG points.
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), KCNMA1. . Gene score misZ 5.0622 (greater than the threshold 3.09). Trascript score misZ 6.5162 (greater than threshold 3.09). GenCC has associacion of gene with cerebellar atrophy, developmental delay, and seizures, generalized epilepsy-paroxysmal dyskinesia syndrome, Liang-Wang syndrome.
BP4
Computational evidence support a benign effect (MetaRNN=0.23657635).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
KCNMA1 | NM_001161352.2 | c.16G>A | p.Gly6Ser | missense_variant | 1/28 | ENST00000286628.14 | NP_001154824.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
KCNMA1 | ENST00000286628.14 | c.16G>A | p.Gly6Ser | missense_variant | 1/28 | 1 | NM_001161352.2 | ENSP00000286628 | A2 |
Frequencies
GnomAD3 genomes AF: 0.0000794 AC: 12AN: 151228Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
12
AN:
151228
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000326 AC: 4AN: 122676Hom.: 0 AF XY: 0.0000298 AC XY: 2AN XY: 67130
GnomAD3 exomes
AF:
AC:
4
AN:
122676
Hom.:
AF XY:
AC XY:
2
AN XY:
67130
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000135 AC: 185AN: 1372060Hom.: 0 Cov.: 33 AF XY: 0.000124 AC XY: 84AN XY: 676418
GnomAD4 exome
AF:
AC:
185
AN:
1372060
Hom.:
Cov.:
33
AF XY:
AC XY:
84
AN XY:
676418
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000794 AC: 12AN: 151228Hom.: 0 Cov.: 32 AF XY: 0.0000948 AC XY: 7AN XY: 73814
GnomAD4 genome
AF:
AC:
12
AN:
151228
Hom.:
Cov.:
32
AF XY:
AC XY:
7
AN XY:
73814
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:5Benign:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Uncertain:3
Uncertain significance, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Aug 02, 2023 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jul 12, 2024 | In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Dec 01, 2021 | - - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 14, 2022 | The c.16G>A (p.G6S) alteration is located in exon 1 (coding exon 1) of the KCNMA1 gene. This alteration results from a G to A substitution at nucleotide position 16, causing the glycine (G) at amino acid position 6 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Generalized epilepsy-paroxysmal dyskinesia syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 16, 2022 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Not Available"; Align-GVGD: "Class C0"). ClinVar contains an entry for this variant (Variation ID: 532940). This variant has not been reported in the literature in individuals affected with KCNMA1-related conditions. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 6 of the KCNMA1 protein (p.Gly6Ser). - |
Intellectual disability Benign:1
Likely benign, no assertion criteria provided | clinical testing | Centre de Biologie Pathologie Génétique, Centre Hospitalier Universitaire de Lille | Jan 01, 2019 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
.;.;.;.;.;.;.;.;.;.;.;T;.;T;.;.;.;.;.;.;.;.;.;.;T;.;.;.;.;.;.;.;.;.;.;.;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;.;D;D;D;D;D;D;D;D;D;D;D;D;T;D
M_CAP
Pathogenic
D
MetaRNN
Benign
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;N;N;N;.;N;.;.;N;N;N;.;.;N;.;.
MutationTaster
Benign
N;N;N;N;N;N
PrimateAI
Pathogenic
D
PROVEAN
Benign
.;.;.;.;.;N;.;.;.;.;.;.;.;N;.;.;.;.;.;.;.;.;.;N;.;.;.;.;.;.;.;.;.;.;.;.;.
REVEL
Benign
Sift
Pathogenic
.;.;.;.;.;D;.;.;.;.;.;.;.;D;.;.;.;.;.;.;.;.;.;D;.;.;.;.;.;.;.;.;.;.;.;.;.
Sift4G
Benign
.;.;.;.;.;T;.;.;.;.;.;T;.;T;.;.;.;.;.;.;.;.;.;T;T;.;.;.;.;T;.;.;.;.;T;T;T
Polyphen
0.021, 0.086, 0.036, 0.062, 0.97
.;.;.;.;.;B;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;B;.;B;B;.;.;B;.;B;.;.;.;.;D;.;.
Vest4
0.29, 0.30, 0.31, 0.27, 0.36, 0.34, 0.33, 0.37
MutPred
Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);Gain of glycosylation at G6 (P = 0.0016);
MVP
0.65
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at